Glucagon-like peptide-1 (GLP-1) is an incretin hormone that performs a wide array of well-characterized antidiabetic actions, including stimulation of glucose-dependent insulin secretion, upregulation of insulin gene expression and improvements in beta-cell survival. GLP-1-receptor agonists have been developed for treatment of diabetes; however, the short biological half-lives of these peptide-based therapeutics requires that frequent injections be administered to maintain sufficient circulating levels. Thus, novel methods of delivering GLP-1 remain an important avenue of active research. It has recently been demonstrated that self-complimentary, double-stranded, adeno-associated virus serotype-8 (DsAAV8) can efficiently transduce pancreatic beta-cells in vivo, resulting in long-term transgene expression. In this study, we engineered a DsAAV8 vector containing a GLP-1 transgene driven by the mouse insulin-II promoter (MIP). Biological activity of the GLP-1 produced from this transgene was assessed using a luciferase-based bioassay. DsAAV8-MIP-GLP-1 was delivered via intraperitoneal injection and beta-cell damage induced by multiple low dose streptozotocin (STZ) administration. Glucose tolerance was assessed following intraperitoneal glucose injections and beta-cell proliferation measured by PCNA expression. Expression of GLP-1 in Min6 beta-cells resulted in glucose-dependent secretion of biologically active GLP-1. Intraperitoneal delivery of DsAAV8-MIP-GLP-1 to mice led to localized GLP-1 expression in beta-cells and protection against development of diabetes induced by multiple low-dose STZ administration. This protection was associated with significant increase in beta-cell proliferation. Results from this study indicate that expression and secretion of GLP-1 from beta-cells in vivo via DsAAV8 represents a novel therapeutic strategy for treatment of diabetes.
Introduction
The incretin hormone glucagon-like peptide (GLP)-1 is produced in intestinal L-cells following post-translational processing of proglucagon by prohormone convertase (PC) 1/3.
1 GLP-1 promotes the maintenance of beta-cell mass through stimulation of cell proliferation and neogenesis while inhibiting apoptosis, [2] [3] [4] and has been shown to be effective in reducing diabetes incidence in models of type-1 diabetes. 5 In addition to its effects on beta-cell survival and growth, GLP-1 acutely stimulates glucose-dependent insulin secretion and can increase insulin gene expression through several mechanisms including upregulation of the transcription factor pancreatic duodenal homeobox-1 (Pdx-1).
6-8 GLP-1 also reduces blood glucose levels by inhibiting glucagon secretion from alpha-cells, an effect likely mediated through increased somatostatin release from delta-cells. 9 Delayed gastric emptying and increased satiety result in inhibition of food intake following activation of GLP-1 receptors in the stomach and CNS, respectively. 2 Wholebody GLP-1-receptor-null mice exhibit moderate glucose intolerance and disrupted islet architecture, suggesting that GLP-1-receptor signaling in islets is required for normal function and development. 10, 11 Clinical studies have shown that diabetic individuals can exhibit decreased GLP-1 secretion, yet physiological responses to this incretin hormone remain largely intact. [12] [13] [14] [15] As a result, therapeutic efficacy of GLP-1-receptor agonists has been demonstrated in individuals with type-2 diabetes. Beneficial effects of GLP-1 in the treatment of type-1 diabetes have also been recognized. 16 While in humans, the glucose-lowering actions are likely mediated largely through delayed gastric emptying, there is additional evidence that inhibition of glucagon secretion may also play a role. 17 In animal models of type-1 diabetes, administration of GLP-1-receptor agonists has been shown to improve glycemia, in part due to increases in beta-cell mass. 5, 18, 19 Native GLP-1, as well as currently available GLP-1-receptor agonists, have short biological half-lives.
Native GLP-1 is degraded within minutes by dipeptidylpeptidase (DPP)-IV, 20, 21 rendering it unfit for use as a subcutaneously administered therapeutic. The synthetic GLP-1-receptor agonists exenatide and liraglutide are resistant to DPP-IV, exhibiting half-lives of approximately 2 and 12 h, respectively. 22, 23 While this increase in half-life facilitates their use as antidiabetic therapies, these drugs must be repeatedly administered through subcutaneous injections to maintain therapeutic levels. In addition, pharmacological increases in circulating levels of these compounds can be associated with side effects including nausea and vomiting. 24, 25 Although nausea typically decreases in severity with prolonged use, it may limit the usefulness of these therapeutics in some individuals.
Recent advances in viral vector technology have led to the development of adeno-associated viral (AAV) vectors that can transduce a wide variety of both dividing and non-dividing cell types. Several different AAV serotypes have now been identified, 26 with serotype-8 exhibiting an ability to efficiently transduce pancreatic tissue. 27, 28 Wang et al. 28 have recently shown that in vivo administration of AAV8 vectors containing enhanced greenfluorescent protein (eGFP) driven by the mouse insulin-II promoter (MIP) results in efficient transduction of pancreatic beta-cells. Furthermore, it has been shown that therapeutic genes can be delivered to beta-cells through intraperitoneal injection of AAV8. 29 Therefore, we sought to generate and deliver a GLP-1 transgene, expressed under the control of the insulin-II promoter, to beta-cells using this novel viral vector. To test the utility of this method of GLP-1 administration, we induced beta-cell apoptosis through low-dose streptozotocin (STZ) administration. We show that following single intraperitoneal injection of this GLP-1 transgene, mice are protected against STZ-induced diabetes, exhibiting significantly reduced impairment of glucose homeostasis and increased in beta-cell proliferation.
Results

MIP-GLP-1 produces biologically active GLP-1 in mouse Min6 beta-cells
The ability of the engineered GLP-1 construct to produce functional GLP-1 was first tested in vitro in transiently transfected Min6 beta-cells. Co-transfection of these cells with MIP-eGFP yielded a transfection efficiency of 27.8±0.5%. Five days after transfection, a glucosestimulated GLP-1 secretion assay was performed in low (2.5 mmol l À1 ) and high (25 mmol l
À1
) glucose. To determine whether biologically active GLP-1 was produced, we developed a GLP-1 bioassay as outlined in Figure 1b . HEK-293 cells were stably transfected with a plasmid encoding the GLP-1 receptor as well as a plasmid containing the luciferase gene driven by the herpes simplex virus thymidine kinase promoter coupled to cAMP-response elements (pHTS-CRE). Activation of the GLP-1 receptor in these cells results in cAMP production and subsequent luciferase gene expression. The luminescence produced following incubation with luciferase substrate can be quantified. This bioassay has a large dynamic range, with a limit of detection of 1 pmol l À1 and an ED 50 of 21.6±7.2 pmol l À1 ( Figure 1b) . As shown in Figure 1c , biologically active GLP-1 was secreted in a glucose-dependent manner from MIP-GLP-1-transfected Min6 beta-cells (25.1±8.8 versus 397.0 ± 103.0 pmol l À1 at low and high glucose, respectively). Secretion of biologically active GLP-1 was not detectable from the mouse hepatoma cell line HEPA 1-6 following infection with the MIP-GLP-1 construct (data not shown).
DsAAV8-MIP-eGFP can transduce mouse islets in vivo
Normal balb/c mice were given a single intraperitoneal injection of DsAAV8-MIP-eGFP at a dose of 1 Â 10 12 viral genomes. Twenty-one days after injection, intra-islet eGFP expression was assessed by immunofluorescence ( Figure 2a ). Robust colocalization of insulin with eGFP was evident, suggesting that the virus directs beta-cellspecific expression of the transgene. Quantification of eGFP expression revealed that 14.3 ± 4.2% (n ¼ 54 islets) of beta-cells expressed immunoreactive eGFP. Conversely, no colocalization of eGFP with glucagon was observed (Figure 2b ), suggesting that alpha-cells do not express the transgene. In addition, no eGFP immunoreactivity was observed in the livers of mice infected with DsAAV8-MIP-eGFP (data not shown). High levels of eGFP expression in the islets of MIP-eGFP transgenic mice have been previously shown to impair beta-cell function 30 In the current study, we did not observe any significant differences in body weight or 4-h fasted blood glucose levels of DsAAV8-MIP-eGFP-treated animals versus vehicle-treated animals during the course of this study (Figures 2b and c) .
DsAAV8-MIP-GLP-1 protects against STZ-induced diabetes in vivo
To assess whether GLP-1 production in beta-cells could alter glucose homeostasis, normal balb/c mice received an intraperitoneal injection of DsAAV8-MIP-GLP-1 at a dose of 1 Â 10 12 viral genomes. Within the first 4 days of injection, GLP-1-expressing animals experienced a 0.43±0.26 g decrease in body weight, whereas vehicletreated animals experienced a 0.22 ± 0.14 g increase in body weight, thus creating a small (B3%), non-significant separation in body weights (P ¼ 0.053) between groups on day 4 ( Figure 3a) . Body weight gain prior to and following the intraperitoneal injections was not significantly different and at no single time point were the body weights significantly different between the two groups. Animals treated with DsAAV8-MIP-GLP-1 tended toward lower fasting plasma glucose levels in the first 2 weeks following injection, with this difference reaching statistical significance (Po0.05) at day 11 post injection. However, this decrease in fasting plasma glucose was transient as blood glucose levels were again not significantly different from those of vehicle-treated mice by day 13 post injection ( Figure 3b) .
To test the ability of beta-cell-derived GLP-1 to protect animals from a diabetogenic stimulus, we employed a 5-day, low-dose STZ protocol (50 mg kg
À1
) to induce islet injury and hyperglycemia. Beta-cell destruction following multiple low-dose STZ treatment has been shown to involve islet infiltration by both macrophages and lymphocytes, 31, 32 thus recapitulating, in part, the known etiology of type-1 diabetes. As shown in Figure 3c , mice receiving either DsAAV-MIP-eGFP or vehicle alone had ) developed within 17 days of the final STZ treatment in both control groups. Conversely, animals treated with DsAAV8-MIP-GLP-1 were protected against development of STZ-induced diabetes, with fasting blood glucose levels not exceeding 15 mmol l À1 during the course of this study ( Figure 3c ). To further characterize the glucose homeostasis of these mice, intraperitoneal glucose-tolerance tests (IPGTTs) were performed prior to and following administration of STZ. Prior to administration of STZ, no significant differences were observed between any of the groups in fasting or peak blood glucose, or in total glucose excursion from the basal value, as measured by the area under the curve (Figures 3d and f) . However, following STZ treatment, peak blood glucose levels during the IPGTTs were significantly higher in the vehicle-and DsAAV8-MIP-eGFP-treated animals as compared with those treated with DsAAV8-MIP-GLP-1 (Figure 3e ), as was the area under the curve (Figure 3f ). Interestingly, animals treated with DsAAV8-MIP-eGFP exhibited significantly greater fasting and peak blood glucose levels as compared with vehicle-treated animals (Figure 3e ), suggesting that expression of eGFP within beta-cells may be detrimental. Plasma GLP-1 levels measured in fed animals treated with the vehicle (11.5 ± 3.5 pmol l
) or with DsAAV8-MIP-GLP-1 (8.0±1.8 pmol l
) were not significantly different, suggesting that in this model, the actions of GLP-1 may be limited to the local islet environment.
In vivo expression of GLP-1 increases beta-cell proliferation following STZ treatment
To verify that intraperitoneal delivery of DsAAV8-MIP-GLP-1 resulted in the production of GLP-1 in beta-cells, islets from mice treated with this virus were isolated and immunohistochemical analysis was performed. As shown in Figure 4 , GLP-1 immunoreactivity could be detected in islets isolated from animals treated with DsAAV8-MIP-GLP-1, but not in islets from animals treated with vehicle alone. Colocalization of GLP-1 and insulin immunoreactivity suggests that expression of the transgene occurs within the beta-cells. Interestingly, two distinct populations of GLP-1-expressing beta-cells were observed in DsAAV8-MIP-GLP-1-treated animals. One subset (indicated with white arrowheads) showed similar levels of GLP-1 and insulin immunoreactivity. The second subset (indicated by white asterisks) expressed higher levels of GLP-1, while exhibiting AAV-mediated expression of GLP-1 in beta-cells MJ Riedel et al weaker insulin immunoreactivity. Since the GLP-1 transgene is driven by the insulin promoter, it is possible that in cells exhibiting high levels of GLP-1 expression, the endogenous insulin promoter has diminished transcription resulting in decreased insulin gene expression. However, our results indicate that the benefits of GLP-1 expression in islets outweighed any potential effect on insulin gene expression in this small subset of beta-cells ( Figure 3 ). As further evidence that expression of the GLP-1 transgene was restricted to islet beta-cells, we showed that GLP-1-producing cells within the islets of animals treated with DsAAV8-MIP-GLP-1 also express Pdx-1 (Figure 4c ), a transcription factor that within islets is expressed primarily in the beta-cells and is absent from alpha-cells. 33 The observation that the majority of GLP-1-positive beta-cells are located in the periphery of the islet, is consistent with the intraperitoneal delivery route and has been observed previously for DsAAV8-mediated transgene expression in islets. 28 To investigate the mechanisms contributing to improved glucose tolerance in mice receiving DsAAV8-MIP-GLP-1, a pancreatic morphometric analysis was performed. Animals expressing beta-cell GLP-1 had similar total insulin-positive area (0.0033 ± 0.0004 in GLP-1-treated animals versus 0.0026 ± 0.0007 in control animals), but trended toward an increase in the total number of insulin-positive areas per mm 2 of pancreatic tissue (15.9 ± 1.5 versus 11.4 ± 1.9 in control animals; P ¼ 0.097) due to significant increase in the number of small insulin-positive clusters (Figures 5a and b) . GLP-1 has been shown to increase beta-cell proliferation in previous studies. 34, 35 Therefore, we assessed nuclear expression of proliferating-cell nuclear antigen (PCNA) as a marker of beta-cell proliferation within islets from both groups. Quantification of PCNA-positive beta-cells revealed an approximate doubling of the proliferation rate from 1.7 ± 0.3% in vehicle-treated animals, to 4.1±0.6% in animals treated with DsAAV8-MIP-GLP-1 (Figures 5c-e) .
Discussion
It has been demonstrated recently that DsAAV8 vectors can be used to direct efficient and long-term expression of transgenes in the pancreas following intraperitoneal administration. 28 Expression can be further restricted within the islet by coupling transgene expression to activation of the MIP, 28 thereby providing an opportunity to specifically target the expression of therapeutic genes within beta-cells. AAV vectors represent an innovative gene therapy tool, having reduced immunogenicity compared with that of adenoviruses, 36 while being capable of directing long-term expression of transgenes both in humans and in mice. 37 -39 AAV8 appears not to be neutralized by antisera directed against other AAV serotypes, and only low levels of neutralizing antibodies against AAV8 have been detected in normal human subjects, 26, 40 suggesting that immune responses that have been observed following AAV2-mediated gene therapy 41 may be minimized following AAV8 administration.
In the current study, we engineered a construct in which GLP-1 expression is driven by the MIP to target GLP-1 production to pancreatic beta-cells. Immunohistochemical analysis of isolated islets from animals infected with DsAAV8-MIP-GLP-1 revealed robust colocalization of GLP-1 with both insulin and Pdx-1, indicating that transgene expression was indeed targeted to the beta-cells. In some islets, we were able to identify rare GLP-1-positive cells that did not express either of these beta-cell markers. This is consistent with previous reports indicating that rodent alpha-cells may be capable of endogenously producing small amounts of mature GLP-1. 42, 43 The expression of GLP-1 within beta-cells of normoglycemic animals did not elicit significant alterations in glucose homeostasis, as indicated by the transient and small reduction in fasting blood glucose levels within treated animals and lack of difference in glucose tolerance following intraperitoneal glucose administration. In STZ-treated animals, despite protection against hyperglycemia, expression of GLP-1 in the betacells did not result in significant alteration in plasma GLP-1 levels when compared with control animals, suggesting that a local environment of increased GLP-1 contributed to the protection against STZ-induced diabetes. In this experimental model and within the timeframe of observation, expression of GLP-1 within the beta-cells was insufficient to cause significant increase in beta-cell mass; however, a trend toward greater number of insulin-positive areas was observed, potentially resulting from an increase in the number of small insulin-positive clusters. In the presence of a significant increase in proliferation within the GLP-1-treated animals, it is possible that these insulin-positive clusters are either the remnants of nearly destroyed islets, or newly forming islets. Despite lack of increase in total beta-cell mass within these animals, it is clear that the remaining functional beta-cell mass is sufficient to prevent the overt diabetes that was observed in the control groups.
Some evidence exists for insulin-promoter activity in the rodent brain, 44 thus potentially leading to extrapancreatic effects of insulin-promoter-driven transgenes. 45 GLP-1 is known to exert a number of physiological effects in the central nervous system, including effects on food intake and satiety. 2 In our study, we noted a transient, non-significant weight loss in animals receiving DsAAV8-MIP-GLP-1, but not in those receiving DsAAV8-MIP-eGFP or the vehicle alone. The spatiotemporal patterning of brain insulin promoter activity remains poorly characterized and a consensus of the relative contribution to CNS insulin levels from de novo synthesis within the brain region is lacking, especially in adult rodents. 46 Thus, although we cannot completely rule out extra-pancreatic expression of GLP-1 following virus administration, given that the virus was delivered to fully developed animals, it is unlikely that significant central expression of the transgene occurred in this study.
The antidiabetic effects of GLP-1 have been wellcharacterized and its therapeutic potential in individuals with type-2 diabetes is well appreciated. 47 GLP-1 has also been recently investigated for its potential benefit in the treatment of type-1 diabetes. Zhang et al. 5 have demonstrated that continuous infusion of GLP-1 in pre-diabetic NOD mice results in significant delay in the onset of diabetes as a result of increased beta-cell proliferation coupled with decrease in beta-cell apoptosis. Furthermore, combination therapies using GLP-1 or exendin-4 with gastrin, 48 anti-lymphocyte serum 49 or anti-CD3 immunotherapy 50 have been shown to restore normoglycemia in acutely diabetic NOD mice by increasing insulin stores and reducing beta-cell apoptosis. Thus, GLP-1-receptor agonists may be useful in therapeutic management of individuals with either type-1 or type-2 diabetes. 
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Currently developed GLP-1-receptor agonists have a short half-life due, in part, to proteolytic cleavage by enzymes including DPP-IV and neutral endopeptidase-24.11. 20, 21, 51 As a result, current GLP-1-receptor agonist therapies require repeated injections to maintain therapeutic plasma concentrations. As an alternative means of raising plasma GLP-1 levels, DPP-IV inhibitors have recently been developed and are now in clinical use for treatment of type-2 diabetes. 52 Gene therapy represents yet another potentially useful means of administering GLP-1. Many studies have examined the potential of endogenous expression of GLP-1 to mitigate the diabetic phenotype in a number of rodent models. The majority of these studies have employed constitutive promoters such as CMV or ubiquitin to drive unregulated expression and secretion of DPP-IV-resistant GLP-1-receptor agonists from tissues such as muscle and liver. [53] [54] [55] Others have fused GLP-1 to various proteins such as IgG or albumin to improve circulating half-lives. 18, 56 In each of these studies, the therapeutic effects of GLP-1 were achieved following systemic increase in GLP-1 levels. Although continuous infusion of GLP-1 in humans has not been associated with decreased receptor activation, the effects associated with chronic and continuous high levels of circulating GLP-1 are likely not yet fully appreciated. In a transplant setting, we have recently shown that production of GLP-1 in alpha-cells following overexpression of PC1/3, improves islet survival and function, leading to improved glucose homeostasis in STZ-treated animals receiving a transplant of these engineered islets. 57 The beneficial effects of GLP-1 in this setting, as well as in the current study, occurred in the absence of changes in circulating GLP-1 levels, indicating that intra-islet production of GLP-1 can create a localized environment capable of significantly improving islet function and survival. The use of the insulin-II promoter to drive GLP-1 expression provides advantages over ubiquitous GLP-1 gene expression by using the beta-cell secretory machinery to yield mealregulated GLP-1 secretion. Therefore, GLP-1 levels in the vicinity of the islets will be highest when blood glucose levels are elevated, thus aiding in the enhancement of glucose-stimulated insulin secretion. Furthermore, basal secretion of GLP-1 from beta-cells, as occurs with insulin, This targeted approach of GLP-1 production in beta-cells using AAV8 vector technology could potentially reduce the frequency of repeat administration required with current GLP-1-based therapies. While wild-type AAV is capable of integration into the human genome at a specific site on chromosome-19, designated AAVS1, 38, 39, 58 the vector used in this study was engineered to lack the Rep protein required for mediating this integration. Pancreatic beta-cells proliferate at a slow rate 59 and long-term episomal maintenance of transgenes delivered through AAV vectors has been demonstrated in slowly dividing cells. Thus, long-term, stable expression of GLP-1 could be expected in human beta-cells following AAV administration. In mice, integration of AAV is less well-defined; 37 however, long-term expression of transgenes delivered through AAV vectors has been observed, 28 possibly through extra-chromosomal maintenance of the viral vector, or through random integration into the genome as can occur in the absence of Rep protein expression. 60 Importantly, integration sites in the mouse genome have not been found within coding regions of known genes, including oncogenes, and infection in mice or humans with AAV has not been linked to any pathological abnormalities. 36, 37 Our data indicate that AAV-mediated expression of GLP-1 in beta-cells following single intraperitoneal administration can mitigate the onset of diabetes in a model of type-1 diabetes. Targeted production of GLP-1 in beta-cells on its own, or coupled with a therapy designed to reduce autoimmune destruction, such as beta-cell expression of interleukin-4 as described by Rehman et al., 29 may represent a novel therapeutic strategy for type-1 diabetes.
Materials and methods
GLP-1 transgene engineering
GLP-1 is liberated from proglucagon following processing by PC1/3 in intestinal L-cells and certain neurons in the CNS. 2 Pancreatic beta-cells express PC1/3 as well as PC2; 61 thus expression of full-length proglucagon in beta-cells would yield glucagon as well as GLP-1 and other peptides. To ensure that only GLP-1 could be produced, SacI sites were engineered upstream and downstream of the glucagon open reading frame within mouse proglucagon (MGC-14058; American Type Culture Collection, ATCC, Manassas, VA, USA) using the QuikChange system (Stratagene, La Jolla, CA, USA). Digestion with SacI, followed by auto-ligation removed the glucagon-encoding sequence. The proglucagon signal sequence was maintained in frame with the GLP-1 open reading frame and a stop codon was engineered downstream of the GLP-1 ORF to prevent expression of GLP-2 ( Figure 1a) . The proglucagon signal sequence was maintained to target GLP-1 to the regulated secretory pathway. To facilitate physiological processing of GLP-1 to its mature form, all surrounding PC1/3 sites were maintained intact. To further limit the actions of GLP-1 to the local islet environment, the GLP-1-coding sequence AAV-mediated expression of GLP-1 in beta-cells MJ Riedel et al was maintained in its wild-type, DPP-IV-sensitive form. This GLP-1 construct was inserted into the AAV vector plasmid DsAAV-MIP-eGFP following excision of the eGFP sequence with AgeI and XbaI. Both vector plasmids contain a 1.13-kb MIP, thus promoting beta-cell-specific transgene expression.
AAV Production
Recombinant AAV (rAAV) vectors were generated according to the triple transfection protocol as previously described. 62 Briefly, HEK-293 cells were transfected with an adenovirus helper plasmid (plAdeno5), an AAV helper plasmid expressing the AAV2 rep and AAV8 cap genes, and a DsAAV plasmid expressing the transgene of interest (eGFP or GLP-1) flanked by inverted terminal repeats and under the control of MIP. Virions were purified by double CsCl-gradient centrifugation and viral genomes were quantified by dot-blot analysis. In the remainder of the text, these vectors will be referred to as DsAAV8-MIP-eGFP and DsAAV8-MIP-GLP-1.
Cell culture and transfections
Min6 beta-cells were a generous gift from Dr Miyazaki and HEPA 1-6 hepatocytes were purchased from ATCC. Both cell types were cultured in high-glucose Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin-G and 100 mg ml 
GLP-1 assays
Min6 beta-cells were plated at 70-80% confluence in sixwell culture plates and transiently transfected with 4 mg each of the DsAAV-MIP-eGFP and DsAAV-MIP-GLP-1 AAV vector plasmids. Five days after transfection, these cells, and non-transfected Min6 beta-cells, were subjected to a 5-h static incubation in the presence of low (2.5 mmol l
À1
) or high (25 mmol l
) glucose. To determine whether GLP-1 produced from the MIP-GLP-1 construct is biologically active, a GLP-1 bioassay was developed. HEK-293 cells stably expressing the human GLP-1 receptor (HEK-hGLP-1R) were generously provided by Dr Jesper Gromada (Novo Nordisk A/S, Denmark). These cells were transfected with the pHTS-CRE plasmid (Biomyx, San Diego, CA, USA) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. These cells (HEK-hGLP-1R-Luc) were grown in high-glucose Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum and 800 mg ml À1 each of hygromycin-B and geneticin (Invitrogen). For GLP-1 measurements, HEK-hGLP-1R-Luc cells were plated in a 96-well plate at a density of 5 Â 10 4 cells per well and incubated overnight at 37 1C. The next day, the medium was aspirated and replaced with 100 ml of either GLP-1 (7-36) amide standards, or medium samples from transfected cells. Following 5-h incubation at 37 1C, a luciferase assay was performed using the Bright-Glo luciferase assay kit (Promega, Madison, MI, USA) according to the manufacturer's instructions. Luminescence was measured using an LMax II microplate reader (Molecular Devices, Sunnyvale, CA, USA). This engineered bioassay exhibited B0.1% crossreactivity for glucose-dependent insulinotropic polypeptide and B3.2% cross-reactivity for glucagon (data not shown).
Plasma samples from mice treated with DsAAV8-MIP-GLP-1 or vehicle alone were collected following a 16-h fast and a 90-min feed, and assayed for total GLP-1 content by total GLP-1 radioimmunoassay (GLP1T-36HK, Linco Research Inc., St Charles, MO, USA). The antisera in this assay cross-react 100% with GLP-1 (7À37) , GLP-1 (7À36) and GLP-1 (9À36) . The detection limit of this assay is 3 mmol l
.
Animals
Male balb/c mice (age 8 weeks) were acquired from the University of British Columbia Animal Care Facility. All experiments were approved by the University of British Columbia Animal Care Committee. Mice were maintained on a standard 12-h light/dark cycle and received standard diet. Blood glucose and body weight were monitored two to three times weekly after a 4-h morning fast. Blood glucose was monitored and survival blood was sampled on restrained un-anaesthetized mice through the saphenous vein. IPGTTs were performed following an overnight fast. Glucose was administered as a 40 % dextrose solution in saline at a dose of 1 mg kg
À1
. Blood glucose levels were assessed at the indicated time points. Total glucose excursion was measured from fasting blood glucose levels and reported as area under the curve.
Immunohistochemistry
Pancreas and liver were harvested following cervical dislocation and fixed in 4% paraformaldehyde overnight at 4 1C. Tissues were subsequently embedded in paraffin wax and sectioned at a thickness of 5 mm. Sections were subjected to 10-min antigen retrieval at 95 1C using a 10-mmol l À1 citrate buffer (pH 6.0). The sections were incubated with rabbit anti-eGFP (1:500; Invitrogen), guinea pig anti-insulin (1:1000; Millipore Corp., Billerica, MA, USA), mouse anti-glucagon (1:1000; Sigma-Aldrich, St Louis, MO, USA), rabbit anti-Pdx-1 (1:1000; generously provided by Joel Habener), mouse anti-GLP-1 (1:20 000; generously provided by Dr David D'Alessio) or mouse anti-PCNA (1:200; BD Biosciences, Mississauga, ON, Canada) as indicated in the text. Primary antibodies were visualized following incubation with secondary antibodies conjugated to AlexaFluor 488 or 594 (1:500; Invitrogen), or using the Vectastatin ABC kit (Vector Laboratories Inc., Burlington, ON, Canada). Images were captured using a Retiga 2000R LCD camera (QImaging, Surrey, BC, Canada) in monochrome and pseudo-colored (fluorescent images) or in RGB format (DAB images) using the OpenLab v5 software (ImproVision, Lexington, MA, USA).
Insulin-positive area quantification
Following DAB staining, pancreas sections were digitally rendered using a ScanScope CS digital slide scanner (Aperio Technologies Inc., Vista, CA, USA) and analyzed using the ImageScope positive pixel count, version 9 algorithm (Aperio Technologies).
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